CB1-IN-4
CAS No. 1429239-98-4
CB1-IN-4 ( DBPR211; DBPR 211; DBPR-211; CB1-IN-1 )
Catalog No. M11811 CAS No. 1429239-98-4
CB1-IN-4 is a potent, selective, peripherally restricted cannabinoid-1 (CB1) receptor antagonist with Ki of 0.3 nM, EC50 of 3.0 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
2MG | 177 | In Stock |
|
5MG | 300 | In Stock |
|
10MG | 429 | In Stock |
|
25MG | 704 | In Stock |
|
50MG | 981 | In Stock |
|
100MG | 1323 | In Stock |
|
500MG | 2655 | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCB1-IN-4
-
NoteResearch use only, not for human use.
-
Brief DescriptionCB1-IN-4 is a potent, selective, peripherally restricted cannabinoid-1 (CB1) receptor antagonist with Ki of 0.3 nM, EC50 of 3.0 nM.
-
DescriptionCB1-IN-4 is a potent, selective, peripherally restricted cannabinoid-1 (CB1) receptor antagonist with Ki of 0.3 nM, EC50 of 3.0 nM; possess a low probability to cross BBB as a peripherally restricted CB1R antagonist, exhibits significant weight-loss efficacy in DIO mice, also displays 163 clean off-target profiles and potential for treating obesity and the related metabolic syndrome.
-
SynonymsDBPR211; DBPR 211; DBPR-211; CB1-IN-1
-
PathwayGPCR/G Protein
-
TargetCannabinoid Receptor
-
RecptorCannabinoid Receptor
-
Research AreaNeurological Disease
-
Indication——
Chemical Information
-
CAS Number1429239-98-4
-
Formula Weight751.67
-
Molecular FormulaC33H31Cl2F3N6O3S2
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESO=C(C1=NN(C2=CC=C(Cl)C=C2Cl)C(C3=CC=C(C#CC4=CC=C(C(F)(F)F)C=C4)S3)=C1CNS(=O)(N5CCCC5)=O)NN6CCCCC6
-
Chemical Name1H-Pyrazole-3-carboxamide, 1-(2,4-dichlorophenyl)-N-1-piperidinyl-4-[[(1-pyrrolidinylsulfonyl)amino]methyl]-5-[5-[2-[4-(trifluoromethyl)phenyl]ethynyl]-2-thienyl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Chang CP, et al. J Med Chem. 2013 Dec 27;56(24):9920-33.
molnova catalog
related products
-
VCE-004.3
VCE-004.3 (VCE004.3) is a novel semi-synthetic cannabidiol derivative behaving as a dual PPARγ/CB2 agonist and CB1 receptor modulator.
-
AM251
AM251 is a potent CB1 receptor antagonist (IC50 = 8 nM, Ki = 7.49 nM) that displays 306-fold selectivity over CB2 receptors; also potent GPR55 agonist (EC50 = 39 nM).
-
EHP-101
VCE-004.8 is a specific dual agonist of PPARγ and CB2 receptor with potent anti-inflammatory activity. VCE-004.8 attenuates adipogenesis and prevents diet-induced obesity.